British Journal of Clinical Pharmacology · 2002 · 53 citations · 27 references
PharmacyPharmacokineticsPharmacologyAnesthesiaBioavailabilityClinical PharmacologyBioavailability AnalysisDrug Half-lifeAdverse Drug EventsContinuous Subcutaneous InfusionMidazolam InfusionPharmacokinetic Bioavailability AnalysisPharmacokinetics Of Intravenous DrugsPharmacokinetics Of Subcutaneous AdministrationSubcutaneous Drug AdministrationSubcutaneous Medication Administration
AIMS: Midazolam is given intravenously for induction of anaesthesia and conscious sedation and by subcutaneous infusion in patients in palliative care units. The objective of the present study was to determine the absolute bioavailability of subcutaneous midazolam and its pharmacokinetics in young, healthy, male volunteers. METHODS: Eighteen volunteers were given single doses of 0.1 mg kg-1 midazolam i.v. and s.c. after a wash-out period of 7-15 days in an open-label, randomized, cross-over study. Blood samples were collected up to 12 h post-infusion. Plasma concentrations of midazolam and of its two metabolites, 1'-OHM and 4-OHM, were assessed using an h.p.l.c.-MS method (LOQ 0.5 ng ml-1 for each analyte). Vital signs, cardiac parameters and oximetry were monitored. Local tolerance was determined and adverse events were also monitored. RESULTS: After s.c. infusion t(max) and C(max) were 0.51 +/- 0.18 h and 127.8 +/- 29.3 ng ml-1 (mean +/- s.d.), respectively. No statistically significant difference was detected in AUC(0, infinity ) after i.v. and s.c. administration. The mean (+/- s.d.) absolute bioavailability of subcutaneous midazolam was 0.96 (+/- 0.14) (CI 0.84, 1.03). Mean (+/- s.d.) t1/2 was similar after s.c. (3.2 (+/- 1.0) h) and i.v. infusion (2.9 (+/- 0.7) h), although a statistically significant difference was reached (P < 0.05). Mean CL and V of i.v. midazolam were 4.4 +/- 1.0 ml min-1 kg-1 and 1.1 +/- 0.2 l kg-1 (mean +/- s.d.), respectively. Plasma concentrations of 1'-OHM were higher than those of 4-OHM. Few mild and transient adverse events were noted and there were no clinically significant effects on EEG, blood pressure and laboratory parameters. CONCLUSIONS: This study has shown that subcutaneous midazolam has excellent bioavailability and that administration of midazolam by this route could be preferable when the intravenous route is inappropriate.
27
Midazolam: pharmacology and uses.
J. G. Reves, Robert J. Fragen, H. Ronald Vinik et al. · PubMed · 1985 · 897 citations
J. G. Rêves, Robert J. Fragen, H. Ronald Vinik et al. · Anesthesiology · 1985 · 747 citations · Full text
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Thomas Kronbach, Daniel Mathys, Makoto Umeno et al. · Molecular Pharmacology · 1989 · 535 citations
Effect of Age, Gender, and Obesity on Midazolam Kinetics
David J. Greenblatt, Ann Locniskar, Jerold S. Harmatz et al. · Anesthesiology · 1984 · 503 citations